Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model

Thrombosis and Haemostasis

Volumn 77, Issue 5, 1997, Pages 1025-1030

  Burke, Sandra E ^a   Lubbers, Nathan L ^a   Nelson, Richard A ^a   Henkin, Jack ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN; SARUPLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOW; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG MECHANISM; FEMORAL ARTERY; FIBRINOLYSIS; HEMOSTASIS; HEPARINIZATION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0030927864     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656097     Document Type: Article

References (28)

1. Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest 1984; 73: 1731-9.
2. Collen D, Stassen JM, Blaber M, Winkler M, Verstraete M. Biological and thrombolytic properties of proenzyme and active forms of human urokinase - III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Thromb Haemost 1984; 52: 27-30.
3. Pannell R, Gurewich V. Pro-urokinase. a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-23.
4. Flameng W, Vanhaecke J, Stump DC, van de Werf F, Holmes W, Guenzler WA, Flohe L, Collen D. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator of recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis. J Am Coll Cardiol 1986; 8: 118-24.
5. Burke SE, Lubbers NL, Nelson RA, Henkin J. Recombinant pro-urokinase requires heparin for optimal clot lysis and restoration of blood flow in a canine femoral artery thrombosis model. Thromb Haemost 1993; 4: 375-80.
6. Gurewich V. Pro-urokinase: physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary action. Semin Thromb Hemost 1988; 14: 110-5.
7. Kirschenbaum JM, Bahr RD. Flaherty JT, Gurewich V, Levine HJ, Loscalzo J, Schumacher RR, Topol EJ, Wahr DW, Braunwald E, Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group. Am J Cardiol 1991; 68: 1564-9.
8. Kasper W, Hohnloser SH, Engler H, Meinertz T, Wilkens J, Roth E, Lang K, Limbourg P, Just H. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase. J Am Coll Cardiol 1990; 16: 733-8.
9. Weaver WD, Hartmann JR, Anderson JL, Reddy PS, Sobolski JC, Sasahara AA. New recombinant glycosylated Prourokinase for treatment of patients with acute myocardial infarction. J Am Coll Cardiol 1994; 24: 1242-8.
10. Bode C, Nordt TK, Runge MS. Thrombolytic therapy in acute myocardial infarction - Selected recent developments. Ann Hematol 1994; 69: 35-40.
11. Sasahara AA, St. Martin CC, Henkin J, Barker WM. Approach to the patient with venous thromboembolism: Treatment with thrombolytic agents. Hematol Oncol Clin North Am 1992; 6: 1141-59.
12. Van de Werf F, Nobuhara M, Collen D. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. Ann Intern Med 1986; 104: 345-8.
13. Tübestein G, Popov S, Wolf H, Welzel D. Effects of pro-urokinase and urokinase on the fibrinolytic system in man. Haemost 1987; 17: 238-44.
14. Kambara H, Kawai C, Kajiwara N, Niitani H, Sasayama S, Kanmatsuse K, Kodama K, Sato H, Nobuyoshi M, Nakashima M et al. Randomized double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction. Circulation 1988; 78: 899-905.
15. Loscalzo J, Wharton TP, Kirshenbaum JM, Levine HJ, Raherty JT, Topol EJ, Ramaswamy K, Kosowsky BD, Salem DN, Ganz P et al. Clot-selective coronary thrombolysis with pro-urokinase. Circulation 1989; 79: 776-82.
16. PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989; 1: 863-8.
17. Bode C, Schuler G, Nordt T, Schonermark S, Baumann H, Richardt G, Dietz R, Gurewich V, Kubler W. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction. Circulation 1990; 81: 907-13.
18. Kasper W, Meinertz T, Hohnloser S, Engler H, Hasler C, Rossler W, Wolf H, Welzel D, Just H, Gurewich V. Coronary thrombolysis in man with prourokinase: improved efficacy with low dose urokinase. Klin Wochenschr 1988; 66: 109-14.
19. Gulba DC, Bode C, Sen S, Topp J, Fischer K, Wolf H, Hecker H. Multicenter dose-finding trial for thrombolysis with urokinase preactivated prourokinase (TCL 598) in acute myocardial infarction. German Preactivated Pro-Urokinase Study Group. Cathet Cardiovasc Diagn 1992; 26: 177-84.
20. Badylak SF, Poehlman E, Williams C, Klabunde RE, Henkin J. Simple canine model of arterial thrombosis with endothelial injury suitable for investigation of thrombolytic agents. J Pharmacol Methods 1988; 19: 293-304.
21. Sutherland JW, Banick DW, Schmakel CO. Stabilized procedure for the determination of urokinase fibrinolylic activity potency. Anal Biochem 1991; 194: 121-9.
22. Friberger P, Knös M. Plasminogen determination in human plasma. In: Chromogenic Peptide Substrates: Chemical and Clinical Usage. Scully MF, Kakkar VV, eds. Edinburgh: Churchill Livingstone 1979: pp 128-40.
23. Edy J, De Cock F, Collen D. Inhibition of plasmin by normal and antiplasmin-depleted human plasma. Thromb Res 1976; 8: 513-8.
24. Vermylen C, De Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clin Chemica Acta 1963; 8: 418-24.
25. Lo K-M, Gillies SD. High level expression of human proteins in murine hybridoma cells: induction by methotrexate in the absence of gene amplification. Biochimica et Biophysica Acta 1991; 1088: 217-24.
26. Credo RB, Burke SE. Fibrinolytic mechanism, biochemistry, and pre-clinical pharmacology of recombinant prourokinase. J Vasc Intervent Radiol 1995; 6: 8-18.
27. Lenich C, Pannell R, Henkin J, Gurewich V. The influence of glycosylation on the catalytic and fibrinolytic properties of pro-urokinase. Thromb Haemost 1992; 68: 539-44.
28. Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 1985; 4: 295-301.